Prosensa extends licence agreement with Leiden University

Licensing deal extended

Prosensa NV, a specialist in RNA therapeutics, has extended its licence agreement on RNA modulation with Leiden University Medical Centre.

In 2003, Prosensa obtained an exclusive worldwide licence from Leiden for the application of its proprietary RNA modulation technology in the field of neuromuscular diseases such as muscular dystrophies. This technology was developed at the Human Genetics department of Prof. Dr. Gert-Jan van Ommen. The recent extension of the licence agreement gives Prosensa the rights to apply the RNA modulation technology for the development of treatments for indications outside the field of neuromuscular disorders.

“Following the proof-of-concept that we obtained with this exciting therapeutic approach for the treatment of Duchenne muscular dystrophy, we see a clear opportunity in applying this powerful technology platform in other indications and building a broad product portfolio for Prosensa,” said Hans Schikan, CEO of Prosensa.

Van Ommen said, “Prosensa has been an ideal partner for us to translate the results of our research into solutions to treat patients, as demonstrated by the tremendous progress that has been made in the development of novel and promising treatments for Duchenne muscular dystrophy.”